ASCO: Enzalutamide Monotherapy in Prostate Cancer Achieves ‘High Response Rate, Marked PSA Decline'
June 5th 2013Monotherapy with enzalutamide (Xtandi) achieved a “high PSA response rate and marked PSA decline” in patients with hormone-naïve prostate cancer after 6 months in a single-arm, multicenter phase II study.
ASCO: NSCLC Therapy Guided by RRM1, ERCC1 Expression Yields No Survival Difference
June 5th 2013Guiding treatment for non–small-cell lung cancer (NSCLC) using expression levels of the proteins RRM1 and ERCC1 led to no difference in either progression-free or overall survival, according to a study presented at the American Society of Clinical Oncology (ASCO) annual meeting.
ASCO: NSCLC Tumor Profiling and Biomarker-Guided Therapy Are Feasible
June 4th 2013A massive French database study shows that genetic tumor profiling in patients with non–small-cell lung cancer (NSCLC) is feasible, and is already helping physicians guide treatment in many patients, according to results presented at the American Society of Clinical Oncology annual meeting in Chicago.
ASCO: Long-Term Tamoxifen Benefit for Breast Cancer Confirmed
June 3rd 2013Women diagnosed with estrogen-receptor (ER)-positive breast cancer who took tamoxifen for 10 years as adjuvant therapy had lower risk of late recurrence and lower risk of death compared to those who took the drug for 5 years. These results corroborate the findings of the international ATLAS trial.
ASCO: Sulforaphane in Prostate Cancer Found Worthy of Further Investigation
June 3rd 2013Treatment with 200 µmol per day of sulforaphane for 20 weeks was “feasible, safe,” and inhibited histone deacetylase (HDAC) function in a single-arm study of 20 patients who had non-castrate biochemical (PSA)-recurrence of prostate cancer despite surgery or radiation.
ASCO: Preview of the Prostate Cancer Sessions
May 30th 2013Ahead of the 2013 ASCO meeting we highlight some of this year's prostate cancer sessions, many of which focus on how best to use the new agents that have been approved recently, as well as looking into new drugs and combinations presented from early trials.
Breast Cancer at ASCO: Latest Trial Results and Emerging Therapies
June 21st 2012CancerNetwork and the journal ONCOLOGY present an exclusive interview with Dr. Kimberly Blackwell, Duke Cancer Institute, who discusses some of the most important information to come out of this year’s meeting and talks about the future of breast cancer research.
ASCO: Paclitaxel Proves Better Than Newer Chemotherapies in Metastatic Breast Cancer
June 12th 2012The results of a randomized phase III trial show paclitaxel beat two newer chemotherapies, nab-paclitaxel and ixabepilone in the treatment of metastatic breast cancer patients who have not had prior systemic therapies.
ASCO: AE37 Peptide Vaccine May Help Prevent Breast Cancer Recurrence
June 12th 2012Women previously treated for HER2-positive breast cancer have lower rates of relapse when given a novel peptide vaccine. The AE37 vaccine showed a 43% risk reduction in these patients after 22 months of follow-up in a phase IIb clinical trial.
Melanoma at ASCO: Latest Treatments and Emerging Therapies
June 11th 2012In this exclusive interview, Michael B. Atkins, MD, director of the Georgetown Lombardi Comprehensive Cancer Center, discusses some of the most important melanoma research to come out of this year’s ASCO meeting and talks about the future of melanoma therapies.
ASCO: Addition of Cetuximab to Pemetrexed Fails to Improve Survival in Advanced NSCLC
June 11th 2012The idea of adding the targeted EGFR inhibitor cetuximab to standard chemotherapy took a hit, as results from the SELECT phase III trial showed no improvement in efficacy when cetuximab was combined with pemetrexed in patients with recurrent or progressive non–small-cell lung cancer.
ASCO: Trastuzumab Tops Lapatinib for First-Line Treatment of HER2-Positive Metastatic Breast Cancer
June 7th 2012Women with metastatic HER2-positive breast cancer treated with a taxane-based chemotherapy in combination with trastuzumab as a first-line of treatment have a longer progression-free survival compared to chemotherapy in combination with lapatinib (Tykerb)
ASCO: Afatinib Improves PFS, Quality of Life in EGFR Mutation-Positive Lung Cancer
June 6th 2012Patients with EGFR mutation-positive lung cancer had improved progression-free survival and better quality of life with new drug afatinib than with standard chemotherapy, according to results from a large phase III trial.
ASCO: FDG-PET Has Poor Accuracy for NSCLC Diagnosis Across Many Centers
June 5th 2012The use of fluorodeoxyglucose positron emission tomography (FDG-PET), for diagnosing lung cancer may have to be rethought. According to an analysis of data from a national prospective trial, FDG-PET has substantially lower sensitivity and specificity than in previously published studies.
ASCO: Controversies in Prostate Cancer-PSA Screening
June 3rd 2012The underlying cost debate surrounding the issue of whether or not to recommend prostate cancer screening is based on the idea that if you use healthcare resources in one area, they’re being diverted from another area by nature of their being a limited pool of funding.
ASCO: Expert Panel Explores Questions Regarding Drug Selection, Drug Sequencing in Advanced Melanoma
June 3rd 2012The new therapies that became available for advanced melanoma over the past year-the anti-CTLA4 antibody ipilimumab (Yervoy) and the selective BRAF inhibitor vemurafenib (Zelboraf)-represent promising new options for these patients, whose prognosis was heretofore almost universally dismal. However, the advent of new treatment strategies has made treatment decisions more complex.